5. Pfizer Inc. (NYSE:PFE)
Number of Hedge Fund Holders — 83
Oncology Growth Gives the Turnaround Story Fresh Evidence
Pfizer Inc. (NYSE: PFE) provided an important update on November 3, reporting third-quarter revenue of approximately $16.6 billion and raising its full-year outlook. Overall revenue was relatively flat operationally, but excluding Comirnaty and Paxlovid, sales increased 7% on the same basis. Launched and acquired products delivered 32% operational revenue growth, indicating that newer businesses are becoming more influential as pandemic-related sales recede. Management now expects annual revenue of $62 billion–$64 billion and adjusted diluted earnings of $2.95–$3.05 per share. Operational growth excludes currency movements, making it useful for assessing the underlying commercial trend.
Oncology supplied some of the strongest product-level contributions. Padcev revenue increased 55% operationally, supported by greater market share in first-line locally advanced or metastatic urothelial cancer and uptake in another bladder cancer setting. Lorbrena revenue rose 43% operationally as its share increased in first-line ALK-positive metastatic non-small cell lung cancer. These figures give investors evidence to examine beyond the broad promise of an expanded cancer pipeline. The commercial challenge is to maintain prescribing momentum while funding additional trials and defending each treatment’s position against competing therapies. An oncology acquisition earns its keep through clinical execution and growing sales, rather than the size of the original announcement.
The investment case combines those growth opportunities with a business still working through a substantial transition. Chief Executive Officer Albert Bourla highlighted “commercial momentum and disciplined execution,” while quarterly adjusted earnings remained $0.87 per share. Investors considering pharmaceutical value stocks should assess the durability of the earnings base before treating a low multiple as an automatic bargain. A cheaper share price can reflect opportunity, but it can also reflect uncertainty about future profits. Cancer drug sales, research productivity, expenses, and capital allocation will determine whether the company’s rebuilding effort produces stronger long-term cash generation.
Ranking rationale — Pfizer Inc. (NYSE: PFE) ranks fifth with 83 hedge fund holders. Growing oncology products and the newly raised annual outlook strengthen its case, while the broader earnings transition and the need to generate returns from acquired and internally developed assets remain key considerations.
